<DOC>
	<DOCNO>NCT00850668</DOCNO>
	<brief_summary>The purpose study evaluate safety side effect study product contains recombinant modify peanut protein ( EMP-123 ) healthy peanut-allergic participant . This first human study . As November 2009 , study longer recruit healthy volunteer recruit individual peanut allergy .</brief_summary>
	<brief_title>Peanut Allergy Vaccine Study Healthy Peanut-allergic Adults</brief_title>
	<detailed_description>Peanut allergy common ailment United States . Research suggest prevalence peanut allergy United States double last 5 year . Currently , effective treatment peanut allergy peanut-free diet quick access self-injectable epinephrine . This study evaluate safety rectally administer product , EMP-123 , consist three recombinant modify peanut protein antigens encapsulate within dead E. coli . E. coli common bacterium find everyone 's colon . E. coli act like package hold modify peanut protein . EMP-123 design act allergy vaccine eventual goal induce tolerance major peanut proteins responsible peanut allergy . This study involve weekly dosing female , pregnancy test occur 48 hour start product administration later study . The study involve two step . Step 1 enroll 5 healthy participant receive four escalate dos study product weekly basis . Participants monitor clinic 2 hour receive dose study product . Each dose visit follow phone interview assess adverse effect symptom . Participants Step 1 maintain home diary record symptoms occur visit . After screen , Step 1 consist five study visit Weeks 1 , 2 , 3 , 4 , 8 . Vital sign , adverse event monitoring , review home diary occur visit . Breathing test occur visit . Stool urine collection occur Weeks 4 8 . The expected duration Step 1 8 week . If safety concern identify conclusion Step 1 , 10 peanut-allergic participant enrol second phase study , Step 2 . Step 2 expect last 20 week . Participants Step 2 receive weekly dose escalation study product 10 week follow administration every 2 week 6 week . Participants remain clinic 2 hour every dose receive . Follow-up continue 4 week conclusion treatment . Each dose visit follow phone interview assess adverse effect symptom . After screen , Step 2 consist 14 study visit . Vital sign , adverse event monitoring , review home diary occur visit . Breathing test occur visit . A skin prick test stool , blood , urine collection occur select visit . As November 2009 , study longer recruit healthy volunteer recruit individual peanut allergy .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>Available duration trial Ability perform spirometry maneuver Agree use effective method contraception duration study For Step 1 participant , regular consumption least 5 gram peanut least twice per month last 6 month prior study entry For Step 2 participant , convince clinical history peanut allergy prick skin test positive peanut . More information criterion find protocol . History severe anaphylaxis Known allergy hydroxypropyl methylcellulose , glycerol , phenol Evidence clinically significant immunosuppressive neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Laboratory evidence liver hematologic disease . Preexisting history autoimmune antibody mediate disease . More information criterion find protocol . Preexisting history autoimmune antibody mediate disease . More information criterion find protocol . Any previous intubation due allergy asthma History ischemic cardiovascular disease Uncontrolled hypertension Significant medical condition , opinion investigator , would interfere study Chronic diarrhea Inability refrain anal intercourse duration trial Use rectal medication study Planned rectal procedure duration study History rectal surgery bleed last 6 month prior study entry History proctitis last 6 month prior study entry History inflammatory bowel disease , celiac disease , eosinophilic esophagitis/gastroenteritis Participation another investigational vaccine drug trial within 30 day prior study study ongoing Medical , occupational , family problem result alcohol illicit drug use last 12 month prior study entry FEV1 value le 80 % predicted Inability discontinue antihistamine skin test Currently allergy immunotherapy Participation interventional study treatment food allergy past 12 month prior study entry Poor control persistent activation atopic dermatitis Use omalizumab nontraditional form allergen immunotherapy immunomodulatory therapy biologic therapy within past 12 month prior study entry Use oral Bblockers , angiotensinreceptor blocker , calcium channel blocker Use immunosuppressive drug within 30 day prior study entry study ongoing Use corticosteroid within 30 day prior study entry Use steroid medication . More information criterion find protocol . History serologic evidence infection HIV1 , HBV , HCV Receipt blood product within past 6 month prior study entry Inability refrain anal intercourse duration study Behavioral , cognitive , psychiatric disease , opinion investigator , would interfere study Pregnant breastfeed Step 1 participant : History allergy food , include peanut Serum peanutspecific IgE great .35 kUa/L screen Prick skin test ( PST ) peanut 3mm diameter screen History asthma Step 2 participant : More mild persistent asthma define protocol . Treatment asthma , include : hospitalization past year asthma emergency room visit past 6 month asthma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Food Allergy</keyword>
	<keyword>Peanut Allergy</keyword>
</DOC>